← Back to Clinical Trials
Recruiting NCT07499180

NCT07499180 A Study on Body Posture and Eye Movements During Screen Usage on Adults Aged 18 to 65 Wearing Various Types of Eyeglasses

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07499180
Status Recruiting
Phase
Sponsor Essilor International
Condition Healthy Adults
Study Type INTERVENTIONAL
Enrollment 69 participants
Start Date 2026-04-07
Primary Completion 2026-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Eye examBody posture and eye movements behaviour of digital device users

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 69 participants in total. It began in 2026-04-07 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical study is to evaluate how adults aged 18 to 65 move their bodies and eyes when they use screens, with various eyeglasses. The main questions it aims to answer are : * How the behaviour between young and presbyopes is different while performing visual tasks on digital devices ? * How the behaviour while performing visual tasks changes according to different types of eyeglasses ? Participants will be asked to take part in an eye exam and do simple visual tasks on digital devices.

Eligibility Criteria

Inclusion Criteria: * Distance refractive error (equivalent sphere) between -3D and +3D * Astigmatism inferior or equal to 1D * Anisometropia inferior or equal to 1.5D * Addition (for presbyopes) between 0.75D and 2.75D * Minimum corrected visual acuity : 8/10 * Stable binocular vision Exclusion Criteria: * Employee of Essilor, Luxottica, GrandVision and their subsidiaries * Aphakia, pseudophakia or ocular surgery * Reported systemic pathology that affects vision * Medical treatment or taking medications that affect vision * Severe ocular pathology declared, involving a loss of visual field as in glaucoma, a loss of acuity * Reported neurological deficit, including a history of seizure or sensorimotor coordination disorders, vestibular or cerebellar pathology * Binocular vision problems such as amblyopia, strabismus, or double vision * Vertebral or cervical troubles * Difficulty to move, vertigo, ocular migraine

Contact & Investigator

Central Contact

Chloé Moger

✉ mogerc@essilor.fr

📞 +33(0)155964827

Principal Investigator

Chloé Moger

PRINCIPAL INVESTIGATOR

Essilor International

Frequently Asked Questions

Who can join the NCT07499180 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Healthy Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07499180 currently recruiting?

Yes, NCT07499180 is actively recruiting participants. Contact the research team at mogerc@essilor.fr for enrollment information.

Where is the NCT07499180 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT07499180 clinical trial?

NCT07499180 is sponsored by Essilor International. The principal investigator is Chloé Moger at Essilor International. The trial plans to enroll 69 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology